Magnetic solutions in AdS5_5 and trace anomalies

We discuss black hole and black string solutions in d=5 Einstein-Yang-Mills theory with negative cosmological constant, proposing a method to compute their mass and action. The magnetic gauge field of these configurations does not vanish at infinity. We argue that this implies a nonvanishing trace for the stress tensor of the dual d=4 theory.Comment: 8 pages, 2 figure

Imaginary-time quantum many-body theory out of equilibrium I: Formal equivalence to Keldysh real-time theory and calculation of static properties

We discuss the formal relationship between the real-time Keldysh and imaginary-time theory for nonequilibrium in quantum dot systems. The latter can be reformulated using the recently proposed Matsubara voltage approach. We establish general conditions for correct analytic continuation procedure on physical observables, and apply the technique to the calculation of static quantities in steady-state non-equilibrium for a quantum dot subject to a finite bias voltage and external magnetic field. Limitations of the Matsubara voltage approach are also pointed out.Comment: 24 pages, 10 figure

A JAK inhibitor for treatment of rheumatoid arthritis: the baricitinib experience

Baricitinib, an oral selective Janus kinase (JAK)1/JAK2 inhibitor, is approved as monotherapy or in combination with methotrexate for treating adults with moderate-to-severe active rheuma-toid arthritis (RA) and provides improvements in clinical signs, symptoms and patient-reported outcomes. Currently, baricitinib is approved for treating RA in more than 75 countries. In sever-al pivotal Phase II and III RA trials (RA-BALANCE, RA-BEGIN, RA-BEAM, RA-BUILD, RA-BEACON, RA-BEYOND), up to seven years of baricitinib treatment was well tolerated and provided rapid and sustained efficacy, which was confirmed in real-world settings. Safety sig-nals for another JAK inhibitor, tofacitinib, have emerged, as observed in the post-marketing Phase IIIb/IV trial Oral Rheumatoid Arthritis Trial (ORAL) Surveillance; safety signals were subsequently highlighted in a retrospective study of baricitinib and consequently new recom-mendations and warnings and precautions for all JAK inhibitors have been issued. Ongoing studies to further characterise and clarify the benefit:risk of JAK inhibitors include registries and controlled trials. This capstone review summarises clinical and real-world data outlining the benefit:risk profile of baricitinib, confirming that the improved disease activity and physical function of patients with RA treated with this JAK inhibitor observed in clinical trials is trans-lated into effectiveness in clinical practice, with a low rate of discontinuations

Cosmological monopoles and non-abelian black holes

We discuss magnetic monopole solutions of the Einstein-Yang-Mills-Higgs equations with a positive cosmological constant. These configurations approach asymptotically the de Sitter spacetime background and exist only for a nonzero Higgs potential. We find that the total mass of the solutions within the cosmological horizon is finite. However, their mass evaluated by using the surface counterterm method outside the cosmological horizon at early/late time infinity generically diverges. Magnetic monopole solutions with finite mass and noninteger charge are found however in a truncation of the theory with a vanishing Higgs field. Both solutions with a regular origin and cosmological black holes are studied, special attention being paid to the computation of the global charges.Comment: 24 pages + 12 figures; figure change

New hairy black hole solutions with a dilaton potential

We consider black hole solutions with a dilaton field possessing a nontrivial potential approaching a constant negative value at infinity. The asymptotic behaviour of the dilaton field is assumed to be slower than that of a localized distribution of matter. A nonabelian SU(2) gauge field is also included in the total action. The mass of the solutions admitting a power series expansion in $1/r$ at infinity and preserving the asymptotic anti-de Sitter geometry is computed by using a counterterm subtraction method. Numerical arguments are presented for the existence of hairy black hole solutions for a dilaton potential of the form $V(\phi)=C_1 \exp(2\alpha_1 \phi)+C_2 \exp(2\alpha_2 \phi)+C_3$, special attention being paid to the case of ${\cal N}=4, D=4$ gauged supergravity model of Gates and Zwiebach.Comment: 12 pages, 4 figures; v2:references added, typos corrected, small changes in Section

Boson stars with negative cosmological constant

We consider boson star solutions in a $D$-dimensional, asymptotically anti-de Sitter spacetime and investigate the influence of the cosmological term on their properties. We find that for $D>4$ the boson star properties are close to those in four dimensions with a vanishing cosmological constant. A different behavior is noticed for the solutions in the three dimensional case. We establish also the non-existence of static, spherically symmetric black holes with a harmonically time-dependent complex scalar field in any dimension greater than two.Comment: 33 pages, 14 eps figures; to be published in Nucl. Phys.

Humidity-tolerant ultrathin NiO gas-sensing films

When the gas sensor active layer film thickness is decreased, increased sensitivity to changes in the adsorbate concentration is expected when measuring the resistance of the layer, in particular when this thickness is on the order of the Debye length of the material (one–tens of nanometers); however, this is demonstrated only for a limited number of materials. Herein, ultrathin NiO films of different thicknesses (8–21 nm) have been deposited via chemical vapor deposition to fabricate gas sensor devices. Sensor performance for a range of NO2 concentrations (800 part-per-billion to 7 part-per-million) was evaluated and an optimum operating temperature of 125 °C determined. The dependence of the potential relative changes with respect to the NO2 concentration and of the sensor signal with respect to the geometrical parameters was qualitatively evaluated to derive a transduction model capable of fitting the experimental results. The selective sensitivity toward NO2 was confirmed by the limited response for different reducing gases, CO, CH4, NH3, and SO2, under optimum operating conditions, and the sensor signal toward NO2 increased with decreasing thickness, demonstrating that the concept of a Debye length dependence of sensitivity is applicable for the p-type semiconductor NiO. In addition, these NiO sensors were exposed to different relative levels of humidity over a wide range of operating temperatures and were found to display humidity tolerance far superior to those in previous reports on SnO2 materials

A JAK inhibitor for treatment of rheumatoid arthritis: The Baricitinib Experience

Baricitinib, an oral selective Janus kinase (JAK)1/JAK2 inhibitor, is approved as monotherapy or in combination with methotrexate for treating adults with moderate-to-severe active rheumatoid arthritis (RA) and provides improvements in clinical signs, symptoms and patient-reported outcomes. Currently, baricitinib is approved for treating RA in more than 75 countries. In several pivotal Phase II and III RA trials (RA-BALANCE, RA-BEGIN, RA-BEAM, RA-BUILD, RA-BEACON, RA-BEYOND), up to seven years of baricitinib treatment was well tolerated and provided rapid and sustained efficacy, which was confirmed in real-world settings. Safety signals for another JAK inhibitor, tofacitinib, have emerged, as observed in the post-marketing Phase IIIb/IV trial Oral Rheumatoid Arthritis Trial (ORAL) Surveillance; safety signals were subsequently highlighted in a retrospective study of baricitinib and consequently new recommendations and warnings and precautions for all JAK inhibitors have been issued. Ongoing studies to further characterise and clarify the benefit:risk of JAK inhibitors include registries and controlled trials. This capstone review summarises clinical and real-world data outlining the benefit:risk profile of baricitinib, confirming that the improved disease activity and physical function of patients with RA treated with this JAK inhibitor observed in clinical trials is translated into effectiveness in clinical practice, with a low rate of discontinuations

A multi-stage genome-wide association study of bladder cancer identifies multiple susceptibility loci.

We conducted a multi-stage, genome-wide association study of bladder cancer with a primary scan of 591,637 SNPs in 3,532 affected individuals (cases) and 5,120 controls of European descent from five studies followed by a replication strategy, which included 8,382 cases and 48,275 controls from 16 studies. In a combined analysis, we identified three new regions associated with bladder cancer on chromosomes 22q13.1, 19q12 and 2q37.1: rs1014971, (P = 8 × 10⁻¹²) maps to a non-genic region of chromosome 22q13.1, rs8102137 (P = 2 × 10⁻¹¹) on 19q12 maps to CCNE1 and rs11892031 (P = 1 × 10⁻⁷) maps to the UGT1A cluster on 2q37.1. We confirmed four previously identified genome-wide associations on chromosomes 3q28, 4p16.3, 8q24.21 and 8q24.3, validated previous candidate associations for the GSTM1 deletion (P = 4 × 10⁻¹¹) and a tag SNP for NAT2 acetylation status (P = 4 × 10⁻¹¹), and found interactions with smoking in both regions. Our findings on common variants associated with bladder cancer risk should provide new insights into the mechanisms of carcinogenesis

A multi-stage genome-wide association study of bladder cancer identifies multiple susceptibility loci.

We conducted a multi-stage, genome-wide association study of bladder cancer with a primary scan of 591,637 SNPs in 3,532 affected individuals (cases) and 5,120 controls of European descent from five studies followed by a replication strategy, which included 8,382 cases and 48,275 controls from 16 studies. In a combined analysis, we identified three new regions associated with bladder cancer on chromosomes 22q13.1, 19q12 and 2q37.1: rs1014971, (P = 8 × 10⁻¹²) maps to a non-genic region of chromosome 22q13.1, rs8102137 (P = 2 × 10⁻¹¹) on 19q12 maps to CCNE1 and rs11892031 (P = 1 × 10⁻⁷) maps to the UGT1A cluster on 2q37.1. We confirmed four previously identified genome-wide associations on chromosomes 3q28, 4p16.3, 8q24.21 and 8q24.3, validated previous candidate associations for the GSTM1 deletion (P = 4 × 10⁻¹¹) and a tag SNP for NAT2 acetylation status (P = 4 × 10⁻¹¹), and found interactions with smoking in both regions. Our findings on common variants associated with bladder cancer risk should provide new insights into the mechanisms of carcinogenesis